XML 20 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating Activities      
Net loss $ (197,878) $ (528,628) $ (652,172)
Adjustments to reconcile net loss to net cash used in operating activities:      
Share-based compensation expense 114,128 105,945 91,085
Loss on conversion of debt     32,890
Loss on extinguishment of development liability 1,949    
Loss on disposal of fixed assets   120  
Forfeiture of accrued interest in exchange of convertible notes     1,287
Depreciation expense 1,797 1,784 1,552
Amortization of discounts for credit facility 1,250    
Amortization of discounts for convertible notes 309 297 459
Accretion of discount to development liability 8,936 25,996 26,917
Changes in operating assets and liabilities:      
Accounts receivable (58,484) (198,715) 2,375
Inventory (10,755) (60,647) (69,397)
Prepaid assets 20,420 (1,870) (11,479)
Other current assets 10,793 14,243 32,936
Other assets 705 11,700 17,490
Right-of-use assets and lease liabilities (277) (80) (65)
Accounts payable 1,089 170 18,689
Accrued expenses and other liabilities 18,152 34,950 (6,312)
Net cash used in operating activities (87,866) (594,735) (513,745)
Investing Activities      
Purchase of property and equipment (403) (773) (1,524)
Proceeds from sale of fixed assets   99  
Purchase of available-for-sale securities     (331,863)
Proceeds from maturity of available-for-sale securities     393,280
Net cash (used in) provided by investing activities (403) (674) 59,893
Financing Activities      
Proceeds from credit facility 365,454    
Payment of issuance cost for credit facility (7,214)    
Repayment of development liability (326,533)    
Proceeds from settlement of capped call 98,763    
Proceeds from issuance of common stock, net of issuance costs     380,120
Proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs   384,387  
Payments for development liability   (55,500) (34,500)
Proceeds from exercise of stock options 14,316 71,274 21,483
Proceeds from issuance of common stock under employee share purchase plan 4,512 5,378 4,238
Payments of employee tax withholding related to equity-based compensation (57) (11,040) (5,682)
Net cash provided by financing activities 149,241 394,499 365,659
Effect of exchange rate changes on cash and cash equivalents (659) 135 (488)
Net increase (decrease) in cash and cash equivalents 60,313 (200,775) (88,681)
Cash, cash equivalents and restricted cash at beginning of period 352,299 553,074 641,755
Cash, cash equivalents and restricted cash at end of period 412,612 352,299 553,074
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:      
Cash and cash equivalents 411,290 351,185 551,801
Restricted cash 1,322 1,114 1,273
Total cash, cash equivalents, and restricted cash 412,612 352,299 553,074
Supplemental disclosure of cash flow information:      
Cash paid for interest 29,368 3,286 5,003
Cash paid for income taxes $ 1,649   4,915
Proceeds from income tax refunds net of income taxes paid   $ 1,759  
Convertible Notes exchanged for common stock     $ 98,086